The initial success of the copyright undeniably reshaped the medication landscape, but placing funds in companies heavily reliant on unbranded versions presents a uncertain picture. While early returns were significant, the cessation of patents and the appearance of cheaper alternatives have eroded sales. Therefore, a thorough analysis of present f